Tarlatamabsmall cell lung cancer
…ncer that have a poor prognosis with limited treatment options. Tarlatamab is a first-in-class, half-life extended delta-like ligand 3 (DL…
8articles mentioning drugs
29drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Tarlatamab ×
Tarlatamab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Tarlatamab
8 articles · page 1 of 1TarlatamabTalquetamabDLL3 TCEtumor treatment
…the experimental window following engraftment with human PBMCs. Tarlatamab (DLL3 TCE) and Talquetamab (GPRC5D TCE) were evaluated in NCG-M…
tarlatamabMayo Clinic Rochestersmall cell lung cancerplatinum-based chemotherapyFDA
…n standard-of-care (SOC) practice.Methods Patients who received tarlatamab at Mayo Clinic Rochester consented to research blood. Immune ph…
tarlatamabatezolizumabdurvalumabcarboplatinetoposideImdelltraES-SCLCsmall cell lung cancerMerck Sharp & Dohme LLC
…age small cell lung cancer. Oncologist 2021;26:433-8.Imdelltra (tarlatamab). Full Prescribing Information, Amgen Inc, Thousand Oaks, CA, U…
teclistamabtarlatamabtalquetamabepcoritamabelranatamabglofitamabmosunetuzumabblinatumomabbsAbsautoimmune disease
…arlatamab, epcoritamab, glofitamab, mosunetuzumab, talquetamab, teclistamab, and elranatamab. Eligibility criteria were abstracted for excl…
tarlatamabtebentafuspsolid tumorsovarian carcinomas
…n solid tumors as evidenced by the approvals of tebentafusp and tarlatamab. Despite these initial clinical successes, there remains a pauc…
tarlatamabDS-7300rovalpituzumabSmall-cell lung cancer (SCLC)SCLC
…metastases and extensive-stage disease. Despite the approval of tarlatamab and ongoing development of DLL3- or B7-H3-targeted ADCs, tumor …
TarlatamabVIB193CatumaxomabTebentafuspLUSCPAADLUADCHOLKIRCsolid tumors+1 more
…itional drugs: the TCR-based Tebentafusp and the antibody-based Tarlatamab. The limited progress in this field is largely attributed to ch…